Natera shares rose 3.6% this morning to a price of $176.61. The stock is still trading within range of its average target price of $169.7, and over the last 52 weeks, it has recorded a 180.3% performance. Analysts have given the Large-Cap Medical Specialities stock target prices ranging from $37.0 to $209.0 dollars per share, with an average rating of buy.
The stock has an average amount of shares sold short at 3.2%, and a short ratio of 2.7. The company's insiders own 3.45% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 93.4% of Natera's shares being owned by this investor type.
Institutions Invested in Natera
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-09-30 | Vanguard Group Inc | 9% | 11,437,007 | $2,019,889,813 |
| 2024-09-30 | Blackrock Inc. | 6% | 8,233,006 | $1,454,031,194 |
| 2024-09-30 | JP Morgan Chase & Company | 4% | 4,632,029 | $818,062,644 |
| 2024-09-30 | Farallon Capital Management LLC | 3% | 4,557,309 | $804,866,345 |
| 2024-09-30 | Fred Alger Management, LLC | 3% | 4,012,000 | $708,559,322 |
| 2024-09-30 | Duquesne Family Office Llc | 3% | 3,566,850 | $629,941,380 |
| 2024-09-30 | State Street Corporation | 3% | 3,494,340 | $617,135,389 |
| 2024-09-30 | Price (T.Rowe) Associates Inc | 2% | 2,870,566 | $506,970,663 |
| 2024-09-30 | Wellington Management Group, LLP | 2% | 2,800,263 | $494,554,450 |
| 2024-09-30 | RTW Investments LP | 2% | 2,593,323 | $458,006,776 |
Besides an analyst consensus of little upside potential, other market factors point to there being positive market sentiment on Natera.
